Valink Therapeutics Analysis
What is Valink Therapeutics?
Valink Therapeutics develops bispecific antibody-drug conjugates (bsADCs) for targeted cancer treatment, enhancing drug delivery and selectivity.
Employees
14
Founded
2021
Revenue
$0-1M
Company Stage
Seed
YC Batch
W21
Product Features & Capabilities
- bispecific antibody drug conjugates (bsADCs), rapid design of drug candidates, LiliumX™ discovery platform, dual targeting for improved function, targeting solid tumors, enhanced payload delivery
Who are the founders of Valink Therapeutics
AS
Arne Scheu
Founder
IK
Irsyad Khairil
Founder
Investors
- P53
- Metaplanet
- Metaplanet Holdings
- RV Invest
- SynBioVen
- Oxonian Ventures
- Acequia Capital
- Hoxton Ventures
- Magnet Capital
See something that needs updating? Suggest edits to this profile.